653. Multiple Myeloma: Clinical and Epidemiological: Poster III

Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI)

Quality-adjusted survival analysis of neurologic events with ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SOC) in patients (Pts) with lenalidomide-refractory multiple myeloma (MM) who received 1-3 prior lines of therapy (LOT)

Incidence and characteristics of infections in patients with multiple myeloma treated with BCMA bispecific antibodies in British Columbia

Spatial biomarkers of CAR T treatment response in relapsed refractory multiple myeloma

Evaluating the CAR hematotox score in patients with refractory relapsed multiple myeloma treated with bispecific T cell engager therapy

Incidence of CMV reactivation in multiple myeloma patients receiving bispecific antibodies

Outcomes of patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant stratified by the 2025 ims IMWG risk classification

Impact of pre transplant functional status and comorbidities on outcomes in individuals with multiple myeloma undergoing autologous hematopoietic cell transplantation

Sustained MRD negativity via multimodal NGS NGF overcomes high risk cytogenetics and predicts long term survival in transplant eligible multiple myeloma A real world cohort study

Applying computational modelling to a high risk multiple myeloma data set to create novel risk stratification groupings

Quantitative morphological parameters of bone marrow plasma cells are predictive of outcomes in plasma cell dyscrasias

Multiple myeloma in adolescents and young adults AYA A comparative analysis of global and u S a epidemiological trends risk factors and projections 1990–2040

Representativeness of clone size measurement by using NGS based immunoglobulin gene rearrangement test in comparison to flow cytometry in clonal plasma cell disorders

The evolution to hepta refractory myeloma involves sequential loss of CD38 BCMA and GPRC5D

Identification of dynamic markers for multiple myeloma in patients with MGUS and T2DM

Atypical IGH CCND1 rearrangements by fluorescent in situ hybridization are associated with higher risk cytogenetic features in multiple myeloma

Treatment of high risk newly diagnosed multiple myeloma with minimal residual disease guided therapy daratumumab carfilzomib lenalidomide and dexamethasone DKRd

Validation of the high risk consensus genomic staging system in the era of bispecific antibodies Role of NGS and cytogenetic reclassification

Baseline characteristics serological and measurable residual disease responses and outcomes in newly diagnosed multiple myeloma patients not planned for autologous stem cell transplant Results from a prospective randomised study using MRD guided therapy

Targeted capture sequencing identifies driver mutations and enables prognostic modeling in multiple myeloma

Main biologic and clinic features at presentation and treatment results in very elderly patients 75 Years with  Multiple myeloma A multicentric experience

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation Long term survivors and impact of induction regimens

A phase 2 trial of teclistamab plus daratumumab combination therapy for high risk smoldering multiple myeloma First pre planned analysis the REVIVE Study

Do chip mutations predict frailty and toxicity in transplant eligible patients with multiple myeloma

Prognostic value of immunoparesis lymphopenia high serum ferritin and suppression of the non involved serum free light chains niFLC in relapsed and refractory multiple myeloma patients RRMM receiving bispecific antibodies

Journey of relapsed or refractory multiple myeloma RRMM after quadruple class exposure QCEx Poor outcomes and high attrition

Extended treatment free hospitalization free time and quality of life benefits with CAR T cell therapy in subgroups of patients with relapsed refractory MM Insights from the KarMMa 3 trial

Novel criteria for evaluating early treatment response with whole body magnetic resonance imaging and prognostic implications in patients with newly diagnosed multiple myeloma

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed refractory multiple myeloma

Machine learning uncovers prognostically distinct myeloma cast nephropathy phenotypes not captured by standard risk stratification systems

GLP 1 agonist use is associated with reduced risk of multiple myeloma in type II diabetes

Prophylactic intravenous immunoglobulin in patients receiving BCMA targeted bispecific antibody therapy for multiple myeloma A systematic review and meta analysis

Baseline cytomegalovirus IgG levels predict reactivation in patients with multiple myeloma receiving elranatamab

A multivariable prediction model for early mortality in multiple myeloma patients with renal impairment